Fruquintinib (Fruzaqla)

Canada’s Drug Agency (CDA-AMC) recommends that Fruzaqla should be reimbursed by public drug plans for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti–vascular endothelial growth factor (anti-VEGF) agent; an anti–epidermal growth factor receptor (anti-EGFR) agent (if RAS wild-type); and either trifluridine-tipiracil or regorafenib if certain conditions are met. Fruzaqla should be covered for use in adult patients with a confirmed diagnosis of colorectal adenocarcinoma that has spread to other parts of the body and who have been previously treated with, or are not candidates for, currently available standard treatments. Patients should have good overall health (performance status) and no unstable neurologic issues related to the central nervous system or need for increasing doses of steroids to control central nervous system disease. Fruzaqla should be prescribed by clinicians who specialize in diagnosing and treating patients with mCRC. Fruzaqla should be stopped if the disease worsens or the patient has severe side effects. The cost of Fruzaqla should be reduced.